Literature DB >> 7978416

Comparison of ondansetron with ondansetron plus dexamethasone in the prevention of postoperative nausea and vomiting.

R McKenzie1, B Tantisira, D J Karambelkar, T J Riley, H Abdelhady.   

Abstract

The purpose of this double-blind, randomized study was to compare the effectiveness of ondansetron plus saline versus ondansetron plus dexamethasone in the prevention of postoperative nausea and vomiting. Of 180 women having general anesthesia for major gynecologic surgery, 89 received intravenous ondansetron, 4 mg, plus saline (Group 1) and 91 received intravenous ondansetron, 4 mg, plus dexamethasone 8 mg (Group 2) during their operation. A complete response, defined as no emesis and no need for rescue antiemetic during the 24-h postoperative period, occurred in 38% of patients in Group 1 and in 52% in Group 2 (P = 0.048). Emesis occurred in 34% of patients in Group 1 and in 15% in Group 2 (P = 0.003). Nausea scores were significantly lower for patients in Group 2 at 2 h (P = 0.023) and at 24 h (P = 0.001). In the ondansetron plus dexamethasone group, 9 out of 10 patients who received propofol for induction of anesthesia had no emesis. The only failure occurred in a patient who had a single emetic episode during the 24th postoperative hour. The combination of ondansetron and dexamethasone was more effective than ondansetron and saline in the prevention of postoperative nausea and vomiting for women having major gynecologic surgery.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7978416     DOI: 10.1213/00000539-199411000-00024

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  20 in total

Review 1.  Risks and benefits of drugs used in the management of postoperative nausea and vomiting.

Authors:  Y F Sung
Journal:  Drug Saf       Date:  1996-03       Impact factor: 5.606

Review 2.  Update on the management of postoperative nausea and vomiting.

Authors:  Anthony L Kovac
Journal:  Drugs       Date:  2013-09       Impact factor: 9.546

3.  Clinical practice guideline for enhanced recovery after colon and rectal surgery from the American Society of Colon and Rectal Surgeons (ASCRS) and Society of American Gastrointestinal and Endoscopic Surgeons (SAGES).

Authors:  Joseph C Carmichael; Deborah S Keller; Gabriele Baldini; Liliana Bordeianou; Eric Weiss; Lawrence Lee; Marylise Boutros; James McClane; Scott R Steele; Liane S Feldman
Journal:  Surg Endosc       Date:  2017-08-03       Impact factor: 4.584

Review 4.  Prevention and treatment of postoperative nausea and vomiting.

Authors:  A L Kovac
Journal:  Drugs       Date:  2000-02       Impact factor: 9.546

Review 5.  RETRACTED ARTICLE: Combination Antiemetic Regimens for Prevention of Postoperative Nausea and Vomiting : Focus on High-Risk Patients.

Authors:  Yoshitaka Fujii
Journal:  Clin Drug Investig       Date:  2002-09       Impact factor: 2.859

6.  How does dexamethasone influence surgical outcome after laparoscopic Nissen fundoplication? A randomized double-blind placebo-controlled trial.

Authors:  M Schietroma; M Giuliani; G Zoccali; F Carlei; F Carnei; Z Bianchi; G Amiccucci; G Amicucci; A G Daniloiu
Journal:  Updates Surg       Date:  2010-07-22

Review 7.  Clinical and economic factors important to anaesthetic choice for day-case surgery.

Authors:  E I Eger; P F White; M S Bogetz
Journal:  Pharmacoeconomics       Date:  2000-03       Impact factor: 4.981

8.  Day-surgery laparoscopic cholecystectomy: factors influencing same-day discharge.

Authors:  J Psaila; S Agrawal; U Fountain; T Whitfield; B Murgatroyd; M F Dunsire; J G Gonzalez; A G Patel
Journal:  World J Surg       Date:  2008-01       Impact factor: 3.352

9.  Preoperative dexamethasone improves surgical outcome after laparoscopic cholecystectomy: a randomized double-blind placebo-controlled trial.

Authors:  Thue Bisgaard; Birthe Klarskov; Henrik Kehlet; Jacob Rosenberg
Journal:  Ann Surg       Date:  2003-11       Impact factor: 12.969

10.  Management of postoperative nausea and vomiting: focus on palonosetron.

Authors:  Neil A Muchatuta; Michael J Paech
Journal:  Ther Clin Risk Manag       Date:  2009-03-26       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.